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Abstract
Introduction
Patients with autoimmune thyroid disease (AITD) show defects in their immune-regulatory
mechanisms. Herein we assessed the expression and function of galectin-1 and galectin-9
(Gal-1, Gal-9) in dendritic cells (DCs) from patients with AITD.
Materials and Methods
Peripheral blood samples from 25 patients with Graves’ disease (GD), 11 Hashimoto’s thy-
roiditis (HT), and 24 healthy subjects were studied. Thyroid tissue samples from 44 patients
with AITD and 22 patients with goiter were also analyzed. Expression and function of Gal-1
and Gal-9 was assessed by quantitative RT-PCR, immunofluorescence and flow cytometry.
Results
A diminished expression of Gal-9, but not of Gal-1, by peripheral blood DCs was observed
in GD patients, mainly in those with Graves´ ophthalmopathy, and a significant negative as-
sociation between disease severity and Gal-9 expression was detected. In addition, the
mRNA levels of Gal-9 and its ligand TIM-3 were increased in thyroid tissue from AITD pa-
tients and its expression was associated with the levels of Th1/Th12/Th17 cytokines. Immu-
nofluorescence studies proved that intrathyroidal Gal-9 expression was confined to DCs
and macrophages. Finally, in vitro functional assays showed that exogenous Gal-9 had a
suppressive effect on the release of Th1/Th2/Th17 cytokines by DC/lymphocyte autologous
co-cultures from both AITD patients and healthy controls.
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Conclusions
The altered pattern of expression of Gal-9 in peripheral blood DCs from GD patients, its cor-
relation with disease severity as well as its ability to suppress cytokine release suggest that
Gal-9 could be involved in the pathogenesis of AITD.
Introduction
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) are the most common autoimmune
thyroid diseases (AITD). In HT a Th1/Th17 response predominates, with a strong inflammato-
ry infiltrate leading to the destruction of thyroid gland [1]. For GD, the main immunological
feature is the presence of auto-antibodies directed against the thyrotropin receptor (TR-Ab),
which stimulate the growth and function of thyroid follicular cells, thus leading to the develop-
ment of goiter and hyperthyroidism. Graves’ ophtalmopathy (GO) is the most frequent extra-
thyroidal manifestation of GD, affecting up to 50% of patients. This condition is mainly due to
inflammation of the orbital connective tissue and extraocular muscles, associated with an in-
creased adipogenesis. Th1 and Th2 lymphocytes may contribute to the pathogenesis of GO at
early and late stages, respectively [2]. In addition, orbital fibroblasts are capable of initiating the
lymphocyte recruitment and tissue remodeling observed in GO [3].
Galectins are a family of highly-conserved glycan-binding proteins that play an important
role in the innate and adaptive immune responses [4]. While an array of soluble mediators are
involved in the pathogenesis of the inflammatory phenomena, different molecules promote its
resolution, by inhibiting leukocyte activation and favouring the clearance of inflammatory cells
[5]. Accumulating evidence indicates that galectins fall into the category of immune regulatory
molecules. Thus, galectin-9 (Gal-9) down-regulates Th1 and Th17 responses and is involved in
the suppression mediated by CD4+ CD25+ T regulatory (Treg) cells, mainly through interac-
tion with the Th1-specific cell surface molecule T-cell immunoglobulin- and mucin domain-
containing molecule-3 (Tim-3) [6, 7]. Several studies with experimental animal models of in-
flammation and autoimmunity, such as immune complex-induced arthritis, allergic asthma
and type-1 diabetes, support the anti-inflammatory role of Gal-9 [7–9]. Likewise, Galectin-1
(Gal-1) acts as a negative regulator of the immune response. In this regard, in vitro and ex vivo
studies have revealed that Gal-1 limits the immune response by promoting apoptosis of Th1
cells, inducing the synthesis of IL-10, and by down-regulating the release of pro-inflammatory
cytokines [10, 11].
Experimental evidence indicates that in AITD there is an imbalance between the activation
of Th1/Th2/Th17 effector lymphocytes and tolerogenic mechanisms, including the dysregula-
tion of Treg cells [12, 13], and abnormalities in tolerogenic dendritic cells (DCs) [14–16]. In
this regard, it is feasible that galectins may play a role in the regulation of the immunogenicity
of DCs in AITD [16]. To examine the potential role of galectins in the immunopathogenesis of
AITD, we analyzed the expression and function of Gal-1 and Gal-9 in DCs from patients with
this condition. We found that the expression of Gal-9 was decreased in peripheral blood con-
ventional DCs (cDCs) from GD, but not HT, patients. Functional assays showed that exoge-
nous Gal-9 was able to inhibit the induction of Th1/Th2/Th17 responses driven by autologous
monocyte-derived DCs (moDCs) from AITD patients and controls. These data suggest that
Gal-9 may play a role in the pathogenesis of AITD.
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Materials and Methods
Patients and samples
Peripheral blood samples from 36 AITD patients were studied, 11 with HT and 25 with GD.
Patients with GD were recruited in a tertiary care referral centre, and a large group of them had
been referred for evaluation of ophtalmopathy and/or thyroid surgery. Peripheral blood sam-
ples were also obtained from 24 healthy controls. Complete clinical and demographic data
were registered in all subjects (S1 Table). At the moment of peripheral blood sampling, one HT
patient was hypothyroid (FT4 = 0.66), two had subclinical hypothyroidism (TSH = 6.30 ±
1.24 μU/mL) and eight were euthyroid (TSH = 1.77 ±1.43 μU/mL). Regarding GD patients,
there was a wide distribution of TSH levels; three were hyperthyroid (FT4 = 2.75 ±0.65ng/dL),
nine had subclinical hyperthyroidism (TSH = 0.10 ±0.12 μU/mL), 13 were euthyroid
(TSH = 2.82 ±1.79 μU/mL), and in 4 patients TSH was above the upper limit of normal
(TSH = 4.9 μU/ml). Thirteen patients were under anti-thyroid therapy (AT) during the study.
Ophthalmopathy was diagnosed by performing a complete eye examination by an ophthal-
mologist at diagnosis and at every follow-up visit, and patients were classified using the Euro-
pean Group on Graves' Ophtalmopathy (EUGOGO)'s activity and severity scales [17]. The
clinical activity score (CAS) was calculated as the sum of the products of activity, and a cut-off
point of 3 out of 7 was used to diagnose active ophtalmopathy[17]. Inactive eye disease was de-
fined as no changes in eye status over the previous 6 months. None of the patients had received
corticosteroids during the previous year. Thirteen patients had Graves’ ophthalmopathy and
seven of them (54%) had active disease (S2 Table). GD patients were classified as severe (goiter
grade 3, and/or active ophthalmopathy with CAS 3, n = 9) and mild (goiter grade 2,
and no ophthalmopathy, n = 14). Fresh thyroid tissue was obtained from four GD patients. All
these patients were euthyroid under carbimazole therapy at the time of surgery. Part of the tis-
sue was maintained in culture medium until processing, while another fragment was frozen,
embedded in OCT medium and stored at -80°C. Serum FT4, TSH levels, and levels of antibod-
ies against thyroglobulin (Tg), thyroperoxidase (TPO) and TR were measured as previously de-
scribed [18]. FT3 was analyzed by FT3 Access DXI 800 analyzer (Beckman Coulter Brea, CA,
USA). Galectin 9 was analyzed by enzyme-linked immunosorbent assay (USCN Life Science,
Hubei, China). This study was approved by the Internal Ethical Review Committee of the Hos-
pital de la Princesa, and all patients signed a written informed consent.
RNA isolation and real-time quantitative PCR (qRT-PCR)
Total RNA was isolated from the frozen tissue with TRIzol reagent (Invitrogen Molecular Re-
search Center Inc. Cincinnati, OH, USA). One microgram of the total RNA was reverse tran-
scribed using High Capacity cDNA Reverse Transcription Kit with RNAse inhibitor (Applied
Biosystems, Carlsbad, CA,USA), following manufacturer’s instructions. Gal-1, Gal-9, Tim-3,
IFN-γ, IL-1β, IL-12β, IL-13 and IL-17 cDNAs were amplified using the Power SYBR GREEN
PCR (Applied Biosystems). Normalization was carried out following internal standards β-actin
and HPRT.
Cells
Peripheral blood mononuclear cells (PBMC) were isolated by Lymphocyte Separation Medium
(Lonza, BioWhittaker, Walkersville, MD, USA) gradient centrifugation. To isolate hematopoi-
etic mononuclear cells infiltrating the thyroid gland (TMC), thyroid specimens were minced
and digested with collagenase (1.0 mg/ml; Roche Molecular Biochemicals, Mannheim, Ger-
many) in Hank´s balanced-salt solution (BioWhittaker, Verviers, Belgium) for 1 h at 37°C.
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Then, cells were passed through a filter (BD Biosciences, Durham, NC, USA), and mononucle-
ar cells were isolated by Lymphocyte Separation Medium. Finally, TMC were washed twice
with PBS, and resuspended in complete RPMI 1640 culture medium (Lonza, Walkersville,
MD, USA). Cell viability was always higher than 95%.
Flow cytometry analysis
To analyze galectin surface expression on peripheral blood DCs, the following mouse anti-
human monoclonal antibodies (mAb) were used: PerCP-HLA-DR, FITC-CD3, FITC-CD14,
FITC-CD16, FITC-CD19, FITC-CD20, V450-CD11c (BD Biosciences) and PE-CD123 (Biole-
gend, San Diego, CA,USA), and goat polyclonal anti-Gal-1 or anti-Gal-9 (R&D systems, Mc-
Kinley, MN,USA), followed by an AlexaFluor 647 donkey-anti-goat (DAG) (Applied
Biosystems, Carlsbad, CA,USA). Gating strategy is shown in S1 Fig. To analyze Tim-3 expres-
sion, lymphocytes were stained with PE-Tim-3, APC-CD3 (Biolegend, San Diego, CA, USA),
FITC-CD4, PerCP-CD8 (BD Biosciences). Thyroid DCs were stained with the following anti-
bodies: PE-Cy7-HLA-DR (Biolegend, San Diego, CA, USA) and Pacific blue-CD11c,
APC-CD123, Pacific orange-CD45 (BD Biosciences, Durham, NC, USA), and anti-Gal-1 or
anti-Gal-9, followed by an AlexaFluor 647-DAG. For negative controls, we incubated cells with
all primary mAb used (except for goat anti-Gal 1 and anti–Gal 9), IgG goat, and then with and
then with Alexa donkey anti-goat (DAG) 647. Dead cells were excluded using 7-Amino-actino-
mycin D (7-AAD) (BD Biosciences, Durham, NC, USA) staining. To block Fc receptors,
PBMC were incubated in an ice bath with normal human IgG (100 μg/ml; Jackson ImmunoRe-
search Europe Ltd.Suffolk, USA) for 30 min. Then, cells were stained with the indicated mAbs,
washed with PBS, fixed in 1% paraformaldehyde and analyzed the same day with a FACSCanto
flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). The mean fluorescence intensity
(MFI) was registered and data was analyzed using the FlowJo software (Ashland, OR, USA).
MFI values of galectin expression were normalized according to the following ratio: MFI value
in cells labelled with the anti-Gal Ab/MFI value of negative control (MFI Gal-1 or—Gal9/ MFI
IgG Goat).
Analysis of galectins in thyroid tissue by immunofluorescence
Frozen thyroid sections were fixed and permeabilized, blocked with normal human IgG, and
incubated with Goat anti-human Gal-1 or-Gal-9 Abs for one hour, followed by an AlexaFluor
488 donkey-anti-goat Ab. CD11c, CD123 and CD163 mAbs (R&D systems, McKinley, MN,
USA) and a rabbit-anti-CD3 (courtesy of Miguel A Alonso-Lebrero, Centro de Biología Molec-
ular Severo Ochoa, CSIC, Madrid Spain) were combined with the proper secondary Abs cou-
pled to Alexa 568 and a biotinylated anti-HLA-DR Ab was used with Streptavidin-647
(Applied Biosystems, Carlsbad, CA,USA). Hoechst 33342 dye was used for cell nuclei staining,
and sections were analyzed in a Leica DMR immunofluorescence microscope (Leica, Wetzlar,
Germany). As negative controls for galectin staining tissue slides, we incubated with all prima-
ry mAb used, except goat anti-Gal-1 or-Gal-9 Abs; followed by the secondary Abs, including
the Alexa Fluor DAG 488 (S2A and S2B Fig). To quantify the percentage of dendritic cells that
expressed Gal-1 or Gal-9, a minimum of 100 cells (CD11c+) or 50 cells (CD123+) per slide
were analyzed.
Functional assays
Peripheral blood lymphocytes (PBLs) isolated by gradient centrifugation using Lymphocyte
Separation Medium (Lonza, BioWhittaker) were co-cultured with autologous monocyte-
derived DCs (moDCs), previously generated in vitro with IL-4 (10 ng/ml) and GM-CSF
Galectin-9 in Graves' Disease
PLOS ONE | DOI:10.1371/journal.pone.0123938 April 16, 2015 4 / 16
(500 U/ml) and preloaded with the superantigen staphylococcal enterotoxin E (SEE)
(0.1 μg/ml). Cells were cultured for 5 days in the presence or absence of human recombinant
Gal-9 (hGal-9 10 μg/ml) (R&D systems, McKinley, MN, USA), where indicated lactose
(50mM) was added. Then, culture supernatants were obtained and the concentrations of IFN-
γ, IL-10, and IL-13 were determined using the BD CBA Human Soluble Protein Flex Set Sys-
tem and the FCAP Array Software Version 3.0 (BD Biosciences, Durham, NC, USA). To study
the effect of hGal-9 on cell death, the co-cultured cells were stained with 7-AAD (BD Biosci-
ences) for three assays and analyzed by flow cytometry.
Statistical methods
Statistical analyses were carried out using GraphPad Prism (GraphPad Software, San Diego,
CA, USA) and SPSS v16.0 (SPSS, Chicago, IL, USA). The association between two variables
was determined with Spearman correlation analyses. Differences between groups were ana-
lyzed with Student’s t-test and one-way analysis of variance (ANOVA) with post-hoc analysis
(Bonferroni's multiple comparisons test). The Mann-Whitney U and Kruskal-Wallis tests were
used when data were not normally distributed.
Results
Expression of Gal-1 and Gal-9 by peripheral blood DCs from AITD
patients
To explore the potential role of galectins in the immunopathogenesis of AITD, we first ana-
lyzed their expression in peripheral blood cDCs (CD11c+) and plasmacytoid DCs (pDCs,
CD123+) from patients with HT and GD, and healthy controls by multi-parametric flow cy-
tometry (Fig 1). There were no differences in the distribution of galectins in relation to age or
gender. We found a significant decrease in the surface expression of Gal-9 on cDCs from GD
patients (MFI 1.20), compared to healthy controls (MFI 1.51, p = 0.0176, Fig 1A). In contrast,
although Gal-9 expression tended to be lower in HT patients compared to controls, no signifi-
cant differences were observed (Fig 1A). Moreover, Gal-9 expression by cDCs was lower in the
group of GD patients with active ophthalmopathy (CAS 3, MFI 1.06) compared to patients
with inactive ophthalmopathy (CAS<3, MFI 1.25) (p = 0.030, Fig 1B and 1C). Accordingly, a
significant inverse correlation between CAS and Gal-9 expression by cDCs was detected [17]
(r = -0.679, p = 0,031, Fig 1D). There were no statistical differences in FT4 or TSH levels be-
tween groups with CAS< 3 and CAS> 3 (p = 0.745 and p = 0.841, respectively). In GD pa-
tients, the expression of Gal-9 was lower in those with severe clinical disease (goiter grade3,
and/or active ophthalmopathy with CAS 3, MFI 1.16), compared to patients with milder
forms of GD (goiter grade2 and CAS3, MFI 1.49) (p = 0.043) (Fig 1E). In addition, no sta-
tistical difference in Gal-9 expression was found between patients who were on antithyroid
treatment and those who were not (p = 0.359). No significant differences were observed for
Gal-1 expression by cDCs (Fig 1A, 1B and 1E). In addition, no differences for Gal-1 and Gal-9
expression by pDCs, were found between patients and controls (Fig 2A), nor between patients
with active or inactive ophtalmopathy (Fig 2B) or between patients with milder of severe clini-
cal disease (Fig 2C). Furthermore, multivariate analysis which considered levels of expression
of galectins by DCs and serum levels of FT4, FT3, TSH, thyroid antibodies, disease activity and
anti-thyroid therapy, did not show any significant association. Likewise, no significant correla-
tion was detected between Gal-9 expression by peripheral DCs and Gal-9 serum levels, either
in patients or healthy controls (data not shown). Finally, when the expression of the Gal-9 li-
gand Tim-3 was analyzed in CD4+ and CD8+ T-lymphocytes, no significant differences
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between patients and controls were detected (Fig 1F) and Tim-3 expression was not associated
with clinical disease features or severity (data not shown).
Expression of Gal-1 and Gal-9 by thyroid DCs from patients with AITD
Triple immunofluorescence staining for MHC-II, CD11c or CD123 and galectins in thyroid
tissue sections revealed expression of Gal-9 by DCs (Figs 3 and 4). Regarding Gal-1, we de-
tected its expression in a minority of CD11c+ MHC-II+ cells (Fig 3A and 3E), while Gal-1 ex-
pression by CD123+ MHC-II+ cells was negligible (Fig 4A and 4E). Gal-9 was mainly detected
in CD11c+MHC-II+ (Fig 3B and 3E) whereas few Gal-9+ CD123+MHC-II+ cells were
Fig 1. Expression of Gal-1 and Gal-9 by peripheral blood cDCs in patients with AITD. Blood samples
were obtained from patients with HT, GD, and healthy controls (C), and Gal-1 and Gal-9 expression by DCs
was analyzed by multiparametric flow cytometry, as described in Materials and Methods. A) Mean
fluorescence intensity (MFI) of Gal-1 and Gal-9 expression in cDCS from GD and HT patients and healthy
controls.B)MFI of Gal-1 and Gal-9 expression in cDCs from patients with GD, classified according to the
presence or absence of active ophthalmopathy (CAS > 3 and CAS < 3 respectively). Galectins expression
corresponds to normalized values (MFI Gal/MFI IgG goat) as described in Material and Methods.C)
Representative flow cytometry dot plots of Gal-9 expression by cDCs from two GD patients, with CAS>3 and
CAS<3 respectively. D) Linear correlation analysis of Gal-9 expression by cDCs from patients with GD and
corresponding CAS. E) Levels of Gal-1 and Gal-9 expression by cDCs from GD patients classified according
to disease severity. F) Expression of the Gal-9 ligand Tim-3 by CD4+ and CD8+ cells in HT, GD and healthy
controls. Differences were evaluated by Kruskal-Wallis and post hoc analyses (Dunnett’s test) or the Mann-
Whitney U test. *p<0.05, **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0123938.g001
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observed (Fig 4B and 4E). When we analyzed the expression of Gal-1 and Gal-9 in other in-
flammatory infiltrating cells, we found no expression on CD3+ cells (S2 Fig), while a small per-
cent of CD163+MHCII+ cells expressed Gal-9, but not Gal-1 (S3 Fig). In addition, we did not
detect Gal-1 or Gal-9 expression on thyrocytes (S2 Fig and S3 Fig). Moreover, in goiter tissue
sections almost no inflammatory infiltrating cells were found and no Gal-1 or Gal-9 staining
was detected (Figs 3C and 3D and 4C and 4D). Expression of Gal-1 and Gal-9 in tissue dendrit-
ic cells was also analyzed by multicolor flow cytometry in CD45+ Lin-, HLA-DR+ CD11+/
CD123+ cells. This analysis showed that both Gal-1 and Gal-9 were expressed in intrathyroidal
cDCs (Fig 3F and 3G); however, their expression in pDCs was negligible (Fig 4F and 4G).
When galectin expression by intrathyroidal cDCs and pDCs was compared with matched pe-
ripheral blood samples from four GD patients, no significant differences were detected. A rep-
resentative patient is shown (Figs 3G and 4G).
Galectin and cytokine expression in the thyroid glands from patients with
AITD
We next conducted a qRT-PCR analysis of Gal-1 and Gal-9 gene expression on thyroid sam-
ples from 40 AITD patients and 22 control samples from patients with goiter (S3 Table). We
found similar levels of Gal-1 mRNA in thyroid tissue from patients with AITD and those with
goiter (Fig 5A). In contrast, thyroid tissue from patients with HT and GD showed an increased
expression of Gal-9 (Fig 5B, p = 0.006 and p<0.0001, compared to goiter). In addition, the ex-
pression of the Gal-9 ligand Tim-3 was significantly increased in GD and in HT compared to
goiter (Fig 5C, p = 0.013 and p<0.0001, respectively), and the expression of this gene was sig-
nificantly higher in HT than in GD (Fig 5C, p = 0.024). Furthermore, a significant association
was detected between levels of Gal-9 and Tim3 gene expression in AITD (Fig 5D, r = 0,493,
p<0.0001). Since effector Th1, Th2 and Th17 lymphocytes seem to play a key role in the patho-
genesis of AITD, we analyzed the mRNA levels of Th1 (IL-1β, IFN-γ, lL-12), Th2 (IL-13) and
Th17 (IL-17) cytokines in thyroid tissue. qRT-PCR analysis revealed a higher expression of IL-
1β in thyroid glands from both GD and TH compared to goiters (p<0.05 in both cases, Fig
5E). Similarly, IFN-γmRNA was increased in the thyroid tissue from both GD and TH patients
(p = 0,033 and p = 0.013, Fig 5F), while IL-12mRNA levels were higher in GD thyroid tissue
compared to controls (p = 0.019, Fig 5G). IL-13 mRNA concentration was higher in GD com-
pared to HT (p = 0.048, Fig 5H). We did not detect any significant difference for IL-17 between
the groups (data not shown). In patients with GD we detected a significant association between
mRNA levels of IL-1β, IFN-γ, lL-12, and IL-13 and those of Gal-9 (Fig 5I). In a multivariate lin-
ear regression analysis including thyroid status, antithyroid therapy and the levels of IL-1b, IL-
12, IL-13 and IFN-γ, a significant association was only found between Gal-9 and IL-12
(r = 0.975, p>0.001). No correlation with Gal-1 expression and cytokine expression was found.
Fig 2. Analysis of Gal-1 and Gal-9 expression in peripheral blood pDCs from AITD patients according
to disease category and activity. Peripheral blood samples were obtained from patients with HT, GD, and
healthy controls, and analyzed for Gal-1 and Gal-9 expression by multiparametric flow cytometry, as
described in Materials and Methods. A) Mean fluorescence intensity (MFI) of Gal-1 and Gal-9 expression by
pDCs in patients with HT and GD and healthy controls.B) MFI of Gal-1 and Gal-9 expression in pDCs from
patients with GD, classified according to ophthalmopathy activity.C) Levels of Gal-1 and Gal-9 expression in
pDCs from patients with GD, classified according to disease severity. Galectins expression corresponds to
normalized values (MFI Gal/ MFI IgG goat) as described in Material and Methods.
doi:10.1371/journal.pone.0123938.g002
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Fig 3. Gal-1 and Gal-9 are expressed by cDCs in thyroid tissue from patients with AITD. Triple immunofluorescence microscopy analysis of thyroid
tissue from a representative AITD patient (A,B) and goiter(C,D) for the expression of Gal-1 or Gal-9 (green), HLA-DR (purple) and CD11c (red); nuclei were
counterstained with Hoechst (blue); arrowheads marks some of the triple-positive cells. E) Percent of conventional dendritic cells expressing Gal-1 or Gal-9,
a minimum of 100 cells (CD11c+) per slide were analyzed.F, G. Flow cytometry analysis of Gal-1 and Gal-9 expression in cDCs. F)Dot plot strategy to select
cDCs; lineage negative cells (CD3, CD14, CD16, CD19 and CD20), CD45+, HLA-DR+, CD11c+.G) Representative histogram of Gal-1 and Gal-9 expression
in cDCs from the thyroid gland. The percentage of Gal-1 and Gal-9 positive cells in cDCs in a representative GD patient (blue line) compared to the negative
control (gray line) is shown. The apparent discrepancy between IHC and flow cytometry studies is very likely due to the different strategy to select cDCs. The
Gal-1 and Gal-9 positive intrathyroidal cDCs (blue line) are compared to peripheral blood expression in the same GD patient (red line).
doi:10.1371/journal.pone.0123938.g003
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Fig 4. Gal-1 and Gal-9 expression by thyroid infiltrating pDCs in thyroid tissue from patients with
AITD. A-D) Triple immunofluorescence microscopy analysis of thyroid gland sections from a representative
patient with AITD (A, B) and goiter (C,D) for the expression of Gal-1 or Gal-9 (green), HLA-DR (purple) and
CD123 (red); nuclei were counterstained with Hoechst (blue); arrowheads marks some of the triple-positive
cells. E) Percent of plasmacytoid dendritic cells expressing Gal-1 or Gal-9, a minimum of 50 cells (CD123+)
per slide were analyzed. F,G. Flow cytometry analysis of Gal-1 and Gal-9 expression in pDCs. F) Dot plot
strategy to select pDCs; lineage negative cells (CD3, CD14, CD16, CD19 and CD20), CD45+, HLA-DR+,
CD123+.G) Representative histogram of Gal-1 and Gal-9 expression in pDCs from the thyroid gland. The
percentage of Gal-1 and Gal-9 positive cells in CD123+ intrathyroidal pDCs in a representative GD patient
(blue line) compared to the negative control (gray line), is shown. The apparent discrepancy between the
results between IHC and flow cytometry studies is very likely due to the different strategy to select
intrathyroidal pDCs. The Gal-1 and Gal-9 positive intrathyroidal CD123+ pDCs (blue line) are compared to
peripheral blood expression in the same GD patient (red line).
doi:10.1371/journal.pone.0123938.g004
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In vitro effect of galectin-9 on cytokine production
Gal-1 and Gal-9 have been described as regulators of the immune responses mediated by Th1,
Th2 and Th17 lymphocytes [19]. To assess this in patients with AITD, we measured IFN-γ,
IL-13 and IL-17 concentrations in the supernatants of co-cultures of peripheral blood lympho-
cytes with autologous moDCs pulsed with SEE, in the presence or absence of hGal-9. We
found that hGal-9 reduced the release of IFN-γ, IL-13 and IL-17 both in controls (p<0.01 in all
cases) and patients (p<0.05 in all cases). The inhibitory effect of hGal-9 on cytokine release
was similar in cells from AITD patients and controls. As expected, the addition of lactose
(50mM), an inhibitor of galectin binding, abolished the regulatory effect of hGal-9 (Fig 6). In
vitro cell death assays showed that the suppressive effect of Gal-9 on cytokine production was
due, at least in part, to the induction of apoptosis (S4 Fig).
Fig 5. Analysis of mRNA levels of Gal-1, Gal-9 and Th1/Th2 cytokines in thyroid glands from AITD
patients. Levels of mRNA of Gal-1, Gal-9, Tim-3 and the indicated Th1/Th2 cytokines were determined by
qRT-PCR analysis in thyroid samples from 40 AITD patients and 22 patients with goiter. A-C) mRNA levels of
Gal-1, Gal-9 and its ligand Tim-3 in thyroid tissue from patients with goiter, HT and GD. D) Correlation
analysis between Tim-3 and Gal-9 mRNA levels in thyroid tissue samples from patients with GD. E-H) mRNA
levels of the indicated Th1 and Th2 cytokines in thyroid tissue from patients with goiter, HT and GD. I)
Correlation analysis between mRNA levels of Gal-9 and the indicated cytokines in thyroid tissue samples
from patients with GD. mRNA levels were normalized using HPRT and β-actin as internal controls.
Differences among groups were analysed by the ANOVA and Bonferroni tests, *p<0.05, **p<0.01,
***p<0.001. Correlation analysis was performed by Pearson or Spearman tests.
doi:10.1371/journal.pone.0123938.g005
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Discussion
Patients with AITD show different defects in their immunoregulatory mechanisms, including
an altered function of Treg lymphocytes and tolerogenic DCs, [13–16]. As galectins play an im-
portant role in regulating DC maturation and immunogenicity [19], we have assessed the ex-
pression and function of Gal-1 and Gal-9 in DCs from patients with AITD. We have found a
diminished expression of Gal-9 by peripheral blood cDCs in AITD patients, mainly in those
with Graves´ ophthalmopathy, and a negative association between severity of eye disease and
Gal-9 expression in cDCs in GD. Galectins have been implicated in the negative regulation of
the immune response, participating in the inhibition of different processes such as lymphocyte
proliferation [20, 21], cellular adhesion and migration [22, 23], the induction of apoptosis, and
modulation of interactions between T cells and antigen-presenting cells [24]. Accordingly, in a
Fig 6. Inhibitory effect of Gal-9 on cytokine release in co-cultures of autologous moDCs with PBLs
from patients with AITD and healthy controls. PBLs were co-cultured with autologous moDCs preloaded
with the superantigen SEE (0,5μg/ml), in the presence or absence of 10μg/ml hGal-9 and 50 mM lactose
(Lact), as stated in Materials and Methods. Then, the concentrations of the indicated cytokines in cell culture
supernatants were determined by bead-based immunoassay and analysed by flow cytometry. C, healthy
controls; GD, Graves’ disease.*p<0.05, **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0123938.g006
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previous report in mice, Seki et al reported that Gal-9 deficient mice show a reduced number of
Treg lymphocytes and an increased effector T cell population, leading to an enhancement of
autoimmune pathology [7]. In addition, administration of recombinant Gal-9 ameliorates dis-
ease activity in various animal models of autoimmunity, including collagen induced arthritis
and autoimmune diabetes [6, 7], by inhibiting the adhesion of inflammatory cells [9]. In AITD,
it is feasible that the diminished expression of Gal-9 by circulating cDCs, observed in our pa-
tients, which is more evident in patients with active GO could contribute to the dysregulated
recruitment of leukocytes to the orbital tissue [3]. Previous studies indicate that Gal-1 has a rel-
evant immunosuppressive role in various experimental models of inflammation and autoim-
munity [10–11], but we did not find any differences in Gal-1 expression in AITD patients.
Although we did not find any significant differences in the expression of galectins regarding
thyroid function or antithyroid drug therapy, we cannot completely rule out an immunomodu-
latory effect of antithyroid drugs on Gal-9 expression. In this regard, it would be interesting to
perform a prospective study on these patients, in order to elucidate the possible effects of hy-
perthyroidism, antithyroid therapy and disease progression on Gal-9 expression.
In thyroid tissue, we found increased levels of Gal-9 mRNA in thyroid samples from AITD
patients that correlated with the presence of infiltrating immune cells. Accordingly, we detected
Gal-9 expression in CD11c+ DCs and in CD163+ macrophages, while CD3+ T cells did not ex-
press Gal-9. In agreement with these results, Gal-9+ cDCs have been reported in the synovial
tissue from patients with rheumatoid arthritis [25]. These data allow us to speculate that in
chronic inflammatory conditions the expression of Gal-9 by infiltrating DCs might correspond
to an immune regulatory mechanism. In addition, we found increased levels of the Gal-9 ligand
Tim-3 in GD thyroid samples. In this regard the Tim-3-Gal-9 pathway is an important regula-
tor of Th1 immunity and tolerance induction. In fact, in an experimental autoimmune enceph-
alomyelitis model, a Th1/Th17 mediated autoimmune condition, the in vivo administration of
an antibody against Tim-3 exacerbated the severity of the disease [26]. Moreover, in NOD
mice, Gal-9 showed a therapeutic potential in type 1 diabetes,as it was capable of inducing apo-
ptosis of CD4+ Tim-3+ Th1 cells [27]. In our AITD patients, although the Gal-9-Tim-3 path-
way was present in the thyroid tissue, it did not seem to be sufficient to counteract the ongoing
autoimmune response. Interestingly, a similar phenomenon apparently occurs with Treg lym-
phocytes, which accumulate in the thyroid gland of AITD patients, but seem unable to sup-
press the inflammatory response [13].
Since galectins can regulate the secretion of some pro- or anti-inflammatory cytokines [4],
we analyzed the expression of different cytokines in AITD thyroid tissue and their relation to
galectins. Our data confirmed an increased synthesis of Th1 and Th2 cytokines, including IL-1,
IFN-γ, IL-12 and IL-13, in the thyroid gland from AITD patients and very interestingly a
positive correlation of these cytokines with Gal-9 gene expression. We also have showed, in co-
culture experiments, a reduced release of Th1, Th12 and Th17 cytokines in the presence of
hGal-9. Gal-9 seems to be involved in a negative feedback loop, where IFN-γ induces Gal-9
[28], which in turn suppresses Th1 cells in vitro, thus preventing prolonged inflammation.Ac-
cordingly, in experimental autoimmune arthritis, treatment with exogenous Gal-9 significantly
decreased the synthesis of the pro-inflammatory cytokines IL-17, IL-12 and IFN-γ, with induc-
tion of Treg cells within the joint [7]. In addition to the immunoregulatory effect of Gal-9 on
cytokine expression, it plays an additional suppressive effect mediated, at least in part, by the
induction of apoptosis. However, as stated above, in the case of AITD, it is conceivable that the
increased expression of Gal-9 in thyroid tissue and the immunoregulatory mechanisms medi-
ated by this molecule are unable to inhibit the synthesis of the pro-inflammatory cytokines and
the ongoing inflammatory reaction. In the case of AITD, it is very difficult to ascertain the role
of each of these immunoregulatory mechanisms for the apparent failure of Gal-9 to inhibit the
Galectin-9 in Graves' Disease
PLOS ONE | DOI:10.1371/journal.pone.0123938 April 16, 2015 13 / 16
ongoing autoimmune reaction. Most evidence that points to Gal-9 as a negative regulator of
immune response has been obtained in animal models of inflammatory diseases, and studies in
humans are scarce. Our data support a model in which Gal-9 down-regulation in human DCs
may contribute to the immune process observed in AITD. The increased recognition of galec-
tins as immunoregulatory molecules could lead to new therapeutic approaches to restore the
immune equilibrium altered in AITD.
Supporting Information
S1 Fig. Gating strategy to identify Gal-9 expression in circulating primary dendritic cells.
Single cell suspensions were prepared from peripheral blood and incubated with next cocktail
of antibodies: FITC-conjugated anti-CD3, anti-CD14, anti-CD16, anti-CD19, anti-CD20;
PerCP-conjugated anti HLA-DR, PE-conjugated anti-CD123 and Pacific Blue-conjugated
anti-CD11c. Gates selected to detect the expression of galectins in cDCs and pDCs is shown.
(TIF)
S2 Fig. Gal-1 and Gal-9 expression by thyroid infiltrating T-lymphocytes. A, B. Negative
controls for immunofluorescence staining. A) Images correspond to tissue section stained only
with secondary antibodies (GAM-568, Strep 647 and DAG488). B) Staining control for galectin
expression. Tissue slides were incubated with biotinylated anti-MHC-II and mouse anti-
CD11c, in the absence of anti-Gal antibodies, followed by goat antimouse (GAM)-568, Strepta-
vidin-647 and DAG-488. C-F. Triple immunofluorescence microscopy analysis of thyroid tis-
sue from an AITD patient (C, D) and patient with goiter(E, F) for the expression of Gal-1
(Green), Gal-9 (green), MHCII (purple) and CD3 (red); nuclei were counterstained with
Hoechst (blue). No detectable Gal-1 or Gal-9 expression was found on thyrocytes. G) Percent
of lymphocytes CD3+ expressing Gal-1 or Gal-9. A minimum of 100 cells (CD3+) per slide
were analyzed.
(TIF)
S3 Fig. Thyroid infiltrating macrophages express Gal-9, but not Gal-1 in thyroid tissue
from patients with AITD. Triple immunofluorescence microscopy analysis of a thyroid from
an AITD patients (A-B) and a goiter (C-D) for the expression of Gal-1 (Green), Gal-9 (green),
MHCII (purple) and CD163 (red); nuclei were counterstained with Hoechst (blue). E,F Immu-
nohistochemical staining for Gal-9 in AITD and in goiter. G) Percentage of macrophages ex-
pressing Gal-1 or Gal-9. A minimum of 100 cells (CD163+MHC+) per slide were analyzed.
(TIF)
S4 Fig. hGal-9 induces cell death. Peripheral blood lymphocytes were co-cultured with autolo-
gous moDCs preloaded with the superantigen SEE, in the presence or not of hGal-9 and lactose
(Lact) and cell viability was determined by staining with 7-AAD (BD Biosciences). Representa-
tive flow cytometry dot plots for each condition.
(TIF)
S1 Table. Characteristics of patients and controls included in the study.
(DOC)
S2 Table. Goiter grade and Ophthalmopathy score in GD patients.
(DOC)
S3 Table. Hormone values, treatment, and intrathyroidal cytokine levels according to clini-
cal diagnosis.
(DOC)
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